401909-52-2

Upstream product

• 67-56-1 methanol 
• 201230-82-2 carbon monoxide 
• 401909-51-1 trifluoro-methanesulfonic acid 5-tert-butyl-2-cyano-phenyl ester 
• 585-34-2 3-tert-butylphenyol 
• 145818-28-6 4-tert-butyl-2-hydroxybenzonitrile 

Downstream Products

• 401909-53-3 (2-aminomethyl-5-t-butylphenyl)methanol 
• 691364-48-4 N-{4-[3-(4-tert-butyl-2-hydroxymethyl-benzyl)-thioureidomethyl]-2-fluoro-phenyl}-methanesulfonamide 
• 401909-54-4 N-{4-[3-(4-tert-butyl-2-hydroxymethyl-benzyl)-thioureidomethyl]-phenyl}-methanesulfonamide 

Relevant academic research and scientific papers

N-4-Methansulfonamidobenzyl-N′-2-substituted-4-tert-butyl-benzyl thioureas as potent vanilloid receptor antagonistic ligands

A series of N-4-methansulfonamidobenzyl-N′-2-substituted-4-tert- butylbenzyl thioureas were prepared for the study of their agonistic/ antagonistic activities to the vanilloid receptor in rat DRG neurons. Their structure-activity relationship reveals that

Novel thiourea derivatives and the pharmaceutical compositions containing the same

The present invention relates to novel thiourca derivatives as a modulator for vanilloid receptor (VR) and the phar- maceutical compositions containing the same. As diseases associated with the activity of vanilloid receptor, pain acute pain, chronic pain, neuropathic pain, post-operative pain, migraine, arthralgia, neuropathies, nerve injury, diabetic neuropathy, neurodegeneration, neurotic skin disorder, stroke, urinary bladder hypersensitiveness, irritable bowel syndrome, a respiratory disorder such as asthma or chronic obstructive pulmonary disease, irritation of skin, eye or mucous membrane, fervescence, stomach-duodenal ulcer, inflam- matory bowel disease and inflammatory diseases can be enumerated. The present invention provides a pharmaceutical composition for prevention or treatment of these diseases.